Rochester, NY 8/10/2009 2:25:29 PM
After Hours - Spectrum Pharmaceuticals, Inc., SPPI - Spectrum Pharmaceuticals Gets the Full Right and Intellectual Property for RenaZorb(R)
Spectrum Pharmaceuticals
Spectrum Pharmaceuticals, Inc. one of the leading commercial-stage biotechnology company focusing primarily on oncology, recently announced that the company has acquired 100% rights to RenaZorb(R) a lanthanum-based nanotechnology compound with potent and selective phosphate binding properties, for all human and non-human indications.
http://StockEinstein.com offers free daily stock alerts on companies ready to run. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
"While focused on the oncology field, we remain opportunistic with our other value-driving assets such as RenaZorb, a drug candidate with the potential to reduce dosage burden for chronic kidney disease patients and enable more effective management of their disease," said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals. "Having full rights to this selective and potent nanotechnology-based drug candidate will facilitate our development and partnering strategy for this asset."
StockEinstein.com has a dedicated team uncovering stocks ready to break and run. We apply time tested criteria and when one of these stocks meets or exceeds our benchmarks, our subscribers are immediately notified directly to their in-box.
This is a free service available only to our subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
During 2009 our alerts have resulted in an average price gain of 80%+.
Disclaimer: Full disclaimer at http://StockEinstein.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinstein, nor any of its affiliates are registered investment advisors or broker dealers.
